Evidence map›Paper›PMID 38108831›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

Therapeutic efficacy of an alpha-particle emitter labeled anti-GD2 humanized antibody against osteosarcoma-a proof of concept study.

Ioanna Liatsou, Yingli Fu, Zhi Li, Mahmud Hasan, Xin Guo, Jing Yu, Joseph Piccolo, Allison Cartee, Hao Wang, Yong Du and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. The molecular blueprint of targeted radionuclide therapy.Nature reviews. Clinical oncology · 2025
    Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Ioanna Liatsou *Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ioanna.liatsou@gmail.com.ORCID 0000-0003-3423-6401
Yingli Fu *Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-1516-1854
Zhi LiDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mahmud HasanDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-0192-6166
Xin GuoDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jing YuDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-3835-7841
Joseph PiccoloDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Allison CarteeDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-2106-0873
Hao WangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-6489-6940
Yong DuDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-0237-6154
Jeffrey BryanDepartment of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA.ORCID 0000-0002-6820-9850
Kathleen GabrielsonDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Dara L KraitchmanDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-0875-5323
George SgourosDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-4553-2866
Johns Hopkins University · USUniversity of Missouri · US

Funding

Dose-Response in Radionuclide TherapyR01CA116477 · NCI · JOHNS HOPKINS UNIVERSITY · PI HOBBS, ROBERT FRANCOIS, SGOUROS, GEORGE · 2006 to 2022
$7.1M
MRI-Guided Cryoablation and Imaging-Guided Intratumoral Delivery of STING Agonist Immunotherapy to Target Localized and Metastatic Canine OsteosarcomaR01CA239124 · NCI · JOHNS HOPKINS UNIVERSITY · PI KRAITCHMAN, DARA L, LADLE, BRIAN H. · 2020 to 2024
$3.1M
Combined Biologic and Radiopharmaceutical Therapy of Breast CancerR01CA187037 · NCI · JOHNS HOPKINS UNIVERSITY · PI SGOUROS, GEORGE · 2015 to 2019
$2.4M
NIH HHS R01 CA116477NIH HHS R01 CA187037NIH HHS R01 CA239124
6 · The paper itself

Abstract

purposeCurrent treatments for osteosarcoma (OS) have a poor prognosis, particularly for patients with metastasis and recurrence, underscoring an urgent need for new targeted therapies to improve survival. Targeted alpha-particle therapy selectively delivers cytotoxic payloads to tumors with radiolabeled molecules that recognize tumor-associated antigens. We have recently demonstrated the potential of an FDA approved, humanized anti-GD2 antibody, hu3F8, as a targeted delivery vector for radiopharmaceutical imaging of OS. The current study aims to advance this system for alpha-particle therapy of OS.

methodsThe hu3F8 antibody was radiolabeled with actinium-225, and the safety and therapeutic efficacy of the [

resultsSignificant antitumor activity was proven in both cases, leading to improved overall survival. In the murine xenograft's case, tumor growth was delayed by 16-18 days compared to the untreated cohort as demonstrated by bioluminescence imaging. The results were further validated with magnetic resonance imaging at 33 days after treatment, and microcomputed tomography and planar microradiography post-mortem. Histological evaluations revealed radiation-induced renal toxicity, manifested as epithelial cell karyomegaly and suggestive polyploidy in the kidneys, suggesting rapid recovery of renal function after radiation damage. Treatment of the two canine patients delayed the progression of metastatic spread, with an overall survival time of 211 and 437 days and survival beyond documented metastasis of 111 and 84 days, respectively.

conclusionThis study highlights the potential of hu3F8-based alpha-particle therapy as a promising treatment strategy for OS.

Indexed as

Bone NeoplasmsOsteosarcomaAnimalsAntibodies, Monoclonal, HumanizedCell Line, TumorDogsHumansMiceProof of Concept StudyX-Ray MicrotomographyAntibodies, Monoclonal, HumanizedAnti-GD2 antibodyHu3F8OsteosarcomaTargeted alpha-particle therapyTheranostics

Identifiers

PMID38108831
OpenAlexW4389880936

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.